Effects of dynorphin A(1-13) on opiate withdrawal in humans

Sheila Specker; Winai Wananukul; Dorothy Hatsukami; Kim Nolin; Lyn Hooke; Mary Jeanne Kreek; Paul R. Pentel

doi:10.1007/s002130050626

Effects of dynorphin A(1-13) on opiate withdrawal in humans

Sheila Specker, Winai Wananukul, Dorothy Hatsukami, Kim Nolin, Lyn Hooke, Mary Jeanne Kreek, Paul R. Pentel

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

The objectives of the current study were to determine 1) the effects of various doses of dynorphin A (1-13) on opiate withdrawal in humans and 2) the safety of dynorphin at these doses. Opiate dependent subjects who had been stabilized on morphine received a single IV dose of placebo, 150, 500 or 1000 μg/kg dynorphin after exhibiting spontaneous withdrawal using a randomized, double-blinded, between-subjects study design. Observer Withdrawal Scores were lower in the 150 and 1000 μg/kg groups as compared to placebo (P < 0.05) but no significant differences were observed on the observer-rated Wang or Sickness Scales. Significant decreases were also found for self-reported symptoms of nervousness, runny nose, sneezing, and painful joints in the 500 μg/kg group. Significant increases in serum prolactin levels were seen after all dynorphin doses; however, these were not dose-related. Dynorphin A (1- 13) was well tolerated and safe, with no changes in physiologic parameters. We conclude that dynorphin A (1-13) has a modest effect in reducing mild opiate withdrawal in humans and is well tolerated at doses up to 1000 μg/kg.

Original language	English (US)
Pages (from-to)	326-332
Number of pages	7
Journal	Psychopharmacology
Volume	137
Issue number	4
DOIs	https://doi.org/10.1007/s002130050626
State	Published - 1998

Bibliographical note

Funding Information:
Acknowledgements The authors wish to acknowledge Margaret Porter, BA, Neil Maniar, BA, and Mithat Gundez, MA for the measurement of prolactin levels. This study was supported by PHS grants DA08067m DA01530, DA00049, DA09259 and Clinical Research Center Grant MO1 RR00400 (National Center of Research Resources).

Keywords

Dynorphin
Human
Opiate withdrawal

Publisher link

10.1007/s002130050626

Find It

Find It at U of M Libraries

Cite this

@article{818029892f0448dd8fb7954f2e7deb20,

title = "Effects of dynorphin A(1-13) on opiate withdrawal in humans",

abstract = "The objectives of the current study were to determine 1) the effects of various doses of dynorphin A (1-13) on opiate withdrawal in humans and 2) the safety of dynorphin at these doses. Opiate dependent subjects who had been stabilized on morphine received a single IV dose of placebo, 150, 500 or 1000 μg/kg dynorphin after exhibiting spontaneous withdrawal using a randomized, double-blinded, between-subjects study design. Observer Withdrawal Scores were lower in the 150 and 1000 μg/kg groups as compared to placebo (P < 0.05) but no significant differences were observed on the observer-rated Wang or Sickness Scales. Significant decreases were also found for self-reported symptoms of nervousness, runny nose, sneezing, and painful joints in the 500 μg/kg group. Significant increases in serum prolactin levels were seen after all dynorphin doses; however, these were not dose-related. Dynorphin A (1- 13) was well tolerated and safe, with no changes in physiologic parameters. We conclude that dynorphin A (1-13) has a modest effect in reducing mild opiate withdrawal in humans and is well tolerated at doses up to 1000 μg/kg.",

keywords = "Dynorphin, Human, Opiate withdrawal",

author = "Sheila Specker and Winai Wananukul and Dorothy Hatsukami and Kim Nolin and Lyn Hooke and Kreek, {Mary Jeanne} and Pentel, {Paul R.}",

note = "Funding Information: Acknowledgements The authors wish to acknowledge Margaret Porter, BA, Neil Maniar, BA, and Mithat Gundez, MA for the measurement of prolactin levels. This study was supported by PHS grants DA08067m DA01530, DA00049, DA09259 and Clinical Research Center Grant MO1 RR00400 (National Center of Research Resources).",

year = "1998",

doi = "10.1007/s002130050626",

language = "English (US)",

volume = "137",

pages = "326--332",

journal = "Psychopharmacology",

issn = "0033-3158",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

TY - JOUR

T1 - Effects of dynorphin A(1-13) on opiate withdrawal in humans

AU - Specker, Sheila

AU - Wananukul, Winai

AU - Hatsukami, Dorothy

AU - Nolin, Kim

AU - Hooke, Lyn

AU - Kreek, Mary Jeanne

AU - Pentel, Paul R.

N1 - Funding Information: Acknowledgements The authors wish to acknowledge Margaret Porter, BA, Neil Maniar, BA, and Mithat Gundez, MA for the measurement of prolactin levels. This study was supported by PHS grants DA08067m DA01530, DA00049, DA09259 and Clinical Research Center Grant MO1 RR00400 (National Center of Research Resources).

PY - 1998

Y1 - 1998

N2 - The objectives of the current study were to determine 1) the effects of various doses of dynorphin A (1-13) on opiate withdrawal in humans and 2) the safety of dynorphin at these doses. Opiate dependent subjects who had been stabilized on morphine received a single IV dose of placebo, 150, 500 or 1000 μg/kg dynorphin after exhibiting spontaneous withdrawal using a randomized, double-blinded, between-subjects study design. Observer Withdrawal Scores were lower in the 150 and 1000 μg/kg groups as compared to placebo (P < 0.05) but no significant differences were observed on the observer-rated Wang or Sickness Scales. Significant decreases were also found for self-reported symptoms of nervousness, runny nose, sneezing, and painful joints in the 500 μg/kg group. Significant increases in serum prolactin levels were seen after all dynorphin doses; however, these were not dose-related. Dynorphin A (1- 13) was well tolerated and safe, with no changes in physiologic parameters. We conclude that dynorphin A (1-13) has a modest effect in reducing mild opiate withdrawal in humans and is well tolerated at doses up to 1000 μg/kg.

AB - The objectives of the current study were to determine 1) the effects of various doses of dynorphin A (1-13) on opiate withdrawal in humans and 2) the safety of dynorphin at these doses. Opiate dependent subjects who had been stabilized on morphine received a single IV dose of placebo, 150, 500 or 1000 μg/kg dynorphin after exhibiting spontaneous withdrawal using a randomized, double-blinded, between-subjects study design. Observer Withdrawal Scores were lower in the 150 and 1000 μg/kg groups as compared to placebo (P < 0.05) but no significant differences were observed on the observer-rated Wang or Sickness Scales. Significant decreases were also found for self-reported symptoms of nervousness, runny nose, sneezing, and painful joints in the 500 μg/kg group. Significant increases in serum prolactin levels were seen after all dynorphin doses; however, these were not dose-related. Dynorphin A (1- 13) was well tolerated and safe, with no changes in physiologic parameters. We conclude that dynorphin A (1-13) has a modest effect in reducing mild opiate withdrawal in humans and is well tolerated at doses up to 1000 μg/kg.

KW - Dynorphin

KW - Human

KW - Opiate withdrawal

UR - http://www.scopus.com/inward/record.url?scp=0031745966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031745966&partnerID=8YFLogxK

U2 - 10.1007/s002130050626

DO - 10.1007/s002130050626

M3 - Article

C2 - 9676891

AN - SCOPUS:0031745966

SN - 0033-3158

VL - 137

SP - 326

EP - 332

JO - Psychopharmacology

JF - Psychopharmacology

IS - 4

ER -

Effects of dynorphin A(1-13) on opiate withdrawal in humans

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this